GENETWORx, a clinical diagnostics laboratory that specializes in molecular pathogen and pharmacogenomic testing, is looking to acquire or strategically partner with other diagnostic laboratories to expand its national platform. GENETWORx offers providers accurate and timely results through its molecular PCR pathogen testing, which is more accurate than standard culture and sensitivity testing, and pharmacogenomic testing, which provides information on genetic differences that affect the metabolism of therapeutic medications. By partnering with other laboratories, GENETWORx aims to improve patient outcomes and lead the future of diagnostic testing.
GENETWORx, a private equity backed laboratory, announces it’s looking to buy or partner with other diagnostics laboratories.
GENETWORx is a clinical diagnostics laboratory based outside of Richmond, VA, that specializes in molecular pathogen and pharmacogenomic testing. GENETWORx offers providers the information they needed to properly prescribe therapeutic options, resulting in improved outcomes.
“We are looking to acquire or strategically partner with laboratories to scale a national platform,” says Steve Crossley, CEO for GENETWORx. “As we look to the future of diagnostic testing, partnering with other laboratories will expand accessibility to patients and, ultimately, improve patient outcomes. We’re excited to be a part of leading the future of diagnostic testing together.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Molecular Pathogen Testing
Molecular PCR pathogen testing generates results that are more accurate than standard culture and sensitivity testing within 24-48 hours of lab receipt.[1] GENETWORx offers clear and concise reports that provide a picture of the type and percent of pathogens causing an infection and, in many cases, identifies antimicrobial resistance regardless of concurrent antibiotic use.
Pharmacogenomic Testing
Pharmacogenomic (PGx) testing is a DNA Medication-Response test that detects genetic differences that affect the metabolism of therapeutic medications and possibilities for adverse events. PGX testing provides pertinent information to ensure patients are prescribed the most effective medication based on drug-metabolism pathways. Understanding how patients metabolize medications and gene/drug interactions may help clinicians improve therapeutic efficacy and reduce adverse effects, while providing insight into potential therapy modifications in certain circumstances.[2]
Source: BioSpace